Prothena nets more cash from Novo Nordisk; Khondrion fails to hit endpoint
A year after Novo Nordisk paid $100 million upfront to grab Prothena’s antibody and wider program in ATTR amyloidosis, the deal has hit a milestone …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
